Tirzepatide Research
Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis
Obesity·March 1, 2026
Yasushi Ishigaki, Masamichi Yamada, Tomotaka Shingaki, Tomonori Oura, Iichiro Shimomura
Summary
Mean weight reduction at 72 weeks: tirzepatide 5mg (-12.0%), 10mg (-22.4%), 15mg (-22.1%) vs placebo (-0.3%). 91.7-100% achieved ≥5% weight loss vs 15.4% placebo.
Study Details
Study Design
Prespecified subpopulation analysis of SURMOUNT-1 RCT
Indication
Obesity or overweight in Japanese adults
Intervention
Once-weekly tirzepatide (5, 10, or 15 mg) vs placebo with lifestyle modification
Species
Human
Sample Size
102 subjects